Evidence map›Paper›PMID 32526885›Full record

ArticleCancers2020

Glutathione S-Transferase pi-1 Knockdown Reduces Pancreatic Ductal Adenocarcinoma Growth by Activating Oxidative Stress Response Pathways.

Rahul R Singh, Jiyan Mohammad, Megan Orr, Katie M Reindl

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. GlutathioneFrontiers in oncology · 2022
    Article
  16. Article
  17. Glutathione S-Transferases in Cancer.Antioxidants (Basel, Switzerland) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Rahul R SinghDepartment of Biological Sciences, North Dakota State University, Fargo, ND 58108, USA.ORCID 0000-0001-5572-8216
Jiyan MohammadDepartment of Biological Sciences, North Dakota State University, Fargo, ND 58108, USA.
Megan OrrDepartment of Statistics, North Dakota State University, Fargo, ND 58108, USA.
Katie M ReindlDepartment of Biological Sciences, North Dakota State University, Fargo, ND 58108, USA.ORCID 0000-0002-7880-3845
North Dakota State University · US

Funding

Targeting CLEC-2/podoplanin as a therapeutic strategy for pancreatic cancerP20GM109024 · NIGMS · NORTH DAKOTA STATE UNIVERSITY · PI Sanku Mallik · 2016 to 2026
$20.5M
GSTP1 as a therapeutic target for pancreatic cancerR15CA249714 · NCI · NORTH DAKOTA STATE UNIVERSITY · PI REINDL, KATIE · 2020 to 2020
$434k
National Science Foundation DMR-1625704NCI NIH HHS R15 CA249714NIGMS NIH HHS P20 GM109024NIH HHS 1P20GM109024
6 · The paper itself

Abstract

Glutathione S-transferase pi-1 (GSTP1) plays an important role in regulating oxidative stress by conjugating glutathione to electrophiles. GSTP1 is overexpressed in breast, colon, lung, and prostate tumors, where it contributes to tumor progression and drug resistance; however, the role of GSTP1 in pancreatic ductal adenocarcinoma (PDAC) is not well understood. Using shRNA, we knocked down GSTP1 expression in three different PDAC cell lines and determined the effect on cell proliferation, cell cycle progression, and reactive oxygen species (ROS) levels. Our results show GSTP1 knockdown reduces PDAC cell growth, prolongs the G

Indexed as

apoptosisERKGSTP1JNKoxidative-stresspancreatic ductal adenocarcinoma (PDAC)ROSSp1therapeutic targets

Identifiers

PMID32526885
PMCPMC7352757
OpenAlexW3035034457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.